Egger Flavio, Targa Federica, Unterholzner Ivan, Grant Russell P, Herrmann Markus, Wiedermann Christian J
Department of Internal Medicine, Central Hospital of Bolzano , BZ, Italy.
Department of Clinical Pathology, Central Hospital of Bolzano , BZ, Italy.
Clin Pract. 2016 Aug 11;6(3):873. doi: 10.4081/cp.2016.873. eCollection 2016 Aug 8.
Non-vitamin K oral anticoagulant (NOAC) therapy may be inappropriate if prescription was incorrect, the patient's physiological parameters change, or interacting concomitant medications are erroneously added. The aim of this report was to illustrate inappropriate NOAC prescription in a 78-year-old woman with non-valvular atrial fibrillation and borderline renal dysfunction who was switched from warfarin to rivaroxaban and subsequently developed bruising with hemorrhagic shock and acute on chronic renal failure. Administration of 4-factor prothrombin complex concentrate effectively reversed coagulopathy and stopped bleeding. Retrospective determination of circulating plasma levels of rivaroxaban and warfarin confirmed that excessive anticoagulation was likely due to warfarin that the patient probably continued to take although rivaroxaban was initiated. Pharmacodynamic interaction between rivaroxaban and warfarin may not only be additive but synergistic. In patients at high risk of complications, judicious prescribing and dosing of NOACs, and regular monitoring of concomitant medications and renal function are highly recommended.
如果处方不正确、患者的生理参数发生变化或错误地添加了相互作用的伴随药物,非维生素K口服抗凝剂(NOAC)治疗可能并不合适。本报告的目的是举例说明一名78岁患有非瓣膜性心房颤动和临界肾功能不全的女性,从华法林转换为利伐沙班后,出现瘀斑并伴有出血性休克和急性慢性肾衰竭,其NOAC处方存在不当之处。给予四因子凝血酶原复合物浓缩物有效地逆转了凝血病并止血。回顾性测定利伐沙班和华法林的循环血浆水平证实,尽管已开始使用利伐沙班,但过量抗凝可能是由于患者可能继续服用的华法林所致。利伐沙班和华法林之间的药效学相互作用可能不仅是相加的,而且是协同的。对于有高并发症风险的患者,强烈建议谨慎开具NOAC的处方和给药,并定期监测伴随药物和肾功能。